An investigation into tetraspanin CD151 as novel prognostic markers in poor outcome endometrial cancer
Year: 2014
Type: dissertation
Study design: Observational Study
Abstract: Background: \nType II endometrial carcinoma, sarcoma and carcinosarcoma account for 10% of uterine malignancies but 50% of recurrences. Survival at recurrence is poor and better \nprognostic markers are needed to guide therapy. The prognostic significance of the novel markers clusterin and tetraspanin CD151 were evaluated in a cohort of poor \noutcome endometrial malignancies, along with oestrogen receptor, progesterone receptor, p53 and human epidermal growth factor receptor 2. Immunohistochemistry profiles and survival outcome between grade 3 endometroid cancers and type 2 cancers were compared. \nMaterial and Methods: \nTissue microarrays constructed from 156 poor outcome uterine malignancies, tested with immunohistochemistry and staining were correlated with clinicopathological, mortality and survival data. \nResults: \nExpression of CD151 was significantly higher in uterine papillary serous and clear cell carcinoma (USPC+CC) compared to grade 3 endometrioid carcinoma, sarcoma or carcinosarcoma. All other markers were not prognostic for survival. Except for CD151, there was no significant difference in marker positivity, age, stage or survival between G3 EEC and UPSC+CC. \nConclusion: \nCD151 is a novel marker in type 2 cancers that may guide therapeutic decisions. These data also suggest that grade 3 EEC is better characterised as a type II endometrial cancer \nand may benefit from similar treatment.
Author: Martin August Voss
Language: English
Subfield: Obstetrics and Gynecology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W634431786